Literature DB >> 15808267

Orbital invasion by periocular basal cell carcinoma.

Igal Leibovitch1, Alan McNab, Timothy Sullivan, Garry Davis, Dinesh Selva.   

Abstract

OBJECTIVES: To present a large series of patients with orbital invasion by periocular basal cell carcinoma (BCC).
DESIGN: Retrospective, noncomparative, interventional case series. PATIENTS: All cases diagnosed with orbital invasion by periocular BCC between January 1985 and July 2004 in 3 Orbital Units in Australia.
METHODS: The clinical records of all patients were reviewed. MAIN OUTCOME MEASURES: Patients' demographics, clinical presentation, histologic subtypes, treatment modalities, recurrence rate, and tumor-related death.
RESULTS: There were 64 patients (49 males) with a mean age of 70+/-13 years. Most tumors (84.4%) were recurrent or previously incompletely excised, and the medial canthus was most frequently involved (56.2%). Signs suggestive of orbital involvement included a mass with bone fixation (35.7%), limitation of ocular motility (30.4%), and globe displacement (17.6%). There were no signs suggestive of orbital invasion in 35.7%. Most patients (51.6%) had infiltrative histologic findings, and perineural invasion was present in 19.3%. Treatment modalities were mainly exenteration alone or combined with radiotherapy. During a mean follow-up period of 3.6 years, 3 cases of recurrence (4.7%) were diagnosed. Only 1 patient (1.6%) died from tumor-related causes.
CONCLUSIONS: Orbital invasion by periocular BCC is an uncommon event that may be associated with significant ocular morbidity and, rarely, death. Because orbital invasion may often be clinically silent, clinicians need to be alert to the possibility in high-risk tumors and consider appropriate imaging. Surgical treatment with exenteration or excision, with or without radiotherapy, results in a low recurrence and mortality rate.

Entities:  

Mesh:

Year:  2005        PMID: 15808267     DOI: 10.1016/j.ophtha.2004.11.036

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  20 in total

Review 1.  Surgical Management of Periocular Cancers: High- and Low-Risk Features Drive Treatment.

Authors:  Richard C Allen
Journal:  Curr Oncol Rep       Date:  2017-09       Impact factor: 5.075

2.  Vismodegib as eye-sparing adjuvant treatment for orbital basal cell carcinoma.

Authors:  Alon Kahana; Francis P Worden; Victor M Elner
Journal:  JAMA Ophthalmol       Date:  2013-10       Impact factor: 7.389

3.  Orbital exenteration for advanced periorbital non-melanoma skin cancer: prognostic factors and survival.

Authors:  R C Gerring; C T Ott; J M Curry; Z B Sargi; S T Wester
Journal:  Eye (Lond)       Date:  2016-10-21       Impact factor: 3.775

4.  Efficacy of Vismodegib (Erivedge) for Basal Cell Carcinoma Involving the Orbit and Periocular Area.

Authors:  Hakan Demirci; Francis Worden; Christine C Nelson; Victor M Elner; Alon Kahana
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2015 Nov-Dec       Impact factor: 1.746

Review 5.  Advanced basal cell carcinoma.

Authors:  Uwe Wollina; Georgi Tchernev
Journal:  Wien Med Wochenschr       Date:  2013-04-16

6.  Determination of the relationship between Basal cell carcinoma and human papilloma virus, based on immunohistochemistry staining method.

Authors:  M Mokhtari; A Mesbah; P Rajabi; M Ail Rajabi; A Chehrei; K Mougouei
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

7.  Orbital exenteration in elderly patients: personal experience.

Authors:  A Croce; A Moretti; L D'Agostino; P Zingariello
Journal:  Acta Otorhinolaryngol Ital       Date:  2008-08       Impact factor: 2.124

Review 8.  Oculoplastic aspects of ocular oncology.

Authors:  C Rene
Journal:  Eye (Lond)       Date:  2012-11-30       Impact factor: 3.775

9.  Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study.

Authors:  Lorenzo Anasagasti-Angulo; Yanelda Garcia-Vega; Silvia Barcelona-Perez; Pedro Lopez-Saura; Iraldo Bello-Rivero
Journal:  BMC Cancer       Date:  2009-07-30       Impact factor: 4.430

10.  Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial.

Authors:  Alon Kahana; Shelby P Unsworth; Christopher A Andrews; May P Chan; Scott C Bresler; Christopher K Bichakjian; Alison B Durham; Hakan Demirci; Victor M Elner; Christine C Nelson; Denise S Kim; Shannon S Joseph; Paul L Swiecicki; Francis P Worden
Journal:  Oncologist       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.